Quote:The only way for us to find out about a sale of Relenza,...

Quote:
The only way for us to find out about a sale of Relenza, is when it is announced by the government and appears in the media.
If that happens, then Biota can asked GSK to confirm this deal, as it is in the media, and has been announced by that government.

There were many sales reported in the media which BTA did not report. Justifying the incompetent BTA management like ostriches burying their heads in the sand seemed to work for some.

Quote: So the deal with relenza is that it has been licensed out to GSK, and hereby Biota has basically nothing to do with it.
They are not allowed to promote it or make media statements about the product.
So Biota can only take the royalties and bank them as they come in, as they have been doing in the past.

On 21 Feb 2007,
Peter Cook announced this to the ASX:
Quote: We’re ASSUMING our Relenza royalties in the second half will be similar to the first half. That’s based on the only concrete advice GSK has given its shareholders which is that it would increase annual Relenza production capacity to 15 million courses. Our analysis of reported sales for the Dec quarter implies GSK’s Relenza production is tracking at about that rate.

There has been UNCONFIRMED reports that GSK may double or treble capacity in calender 2007, and although we have no knowledge of the potential timing, we know GSK’s North Carolina facility has been commissioned.

On the marketing front……..” Read how Peter Cook speculated on sales, and promoted the product in the ASX release:
http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=00695198

Is Peter Cook here spruiking that he is Quote:"hereby Biota has basically nothing to do with it.
They are not allowed to promote it or make media statements about the product. LOL

A new CEO at BTA? Wow that’s real good news!
A new CEO at GSK (Andrew Witty)? The 190million planed production under Mr Witty pales in comparison to 400m planned and achieved by Roche. Under Mr Witty, Relenza market share had dropped backed to 10% because the availability of Relenza is limited by production capacity. Under Mr Witty, BTA holders are going to get zilch from GSK license in China because GSK did not provide Simcere the know-how to manufacture Relenza.

Such blatant nonsense had been repeatedly posted. The thread can be found here:
http://www.hotcopper.com.au/post_single.asp?fid=1&tid=934492&msgid=5207727